FDA Approves IMAAVY as First Treatment for Warm Autoimmune Hemolytic Anemia

The U.S. Food and Drug Administration (FDA) has approved IMAAVY, marking the first-ever treatment for adults diagnosed with warm autoimmune hemolytic anemia, a rare blood disorder. This approval expands Johnson & Johnson's rare disease portfolio and provides a new therapeutic option for patients who previously had limited treatment choices for this condition.